Most IPOX Indexes surge into year-end / Big jump in China-linked exposure propels IPOX International (IPXI) to close at all-time high. ETFs in focus: FPXI, FPX. Big gains in China-linked exposure and special situations propelled select IPOX Indexes last week, with the IPOX International (IPXI) – underlying for the First Trust International IPO ETF (FPXI) – adding 1.56% to 37.24% YTD, a fresh all-time high and a massive 1730 bps. ahead of the international market YTD. Relative strength extended to the IPOX 100 U.S. (IPXO), with the benchmark for U.S. IPOs, Spin-offs and IPO M&A activity adding 0.98% to 26.42% YTD, 70 bps. ahead of the S&P 500 (SPX) – yardstick for U.S. stocks – on the week. Big gains in specialty stocks contributed to the strong showing, including high-end anorak jacket maker Canada Goose (GOOS US: 12.33%), H.K.- traded packed foods producer Dali Foods (3799 HK: 10.99%), US brick-and-mortar retailers Burlington Stores (BURL US: 7.67%) and Ollies Bargain Outlet (OLLI US: 6.40) or social networkers/perceived takeover plays Twitter (TWTR US: 10.03%) or Tinder-owner Match Group (MTCH US: 8.43%). We note the big upside in select biotech’s tracked by IPOX, including Avexis (AVXS US: 10.34%) and Genscript (1548 HK: 53.02%). Payment processor Square (SQ US: -5.10%) declined on weakness on digital currencies.
IPOX 100 U.S. Investing with the 5-star FPX ETF since 2006:
|IPOX Price Returns (%)||Last Week||Q3 2017||YTD 2017|
|Exposure: Global/International (xUS) (USD)|
|IPOX Global (IPGL50)||0.96||8.63||28.70|
|IPOX International (IPXI)*||1.49||9.49||37.15|
|Exposure: United States (USD)|
|IPOX Composite U.S. (IPXC)*||1.45||8.86||34.50|
|IPOX 100 U.S. (IPXO)*||0.98||7.06||26.42|
|IPOX 30 U.S. (IPXT)||0.45||7.99||27.43|
|Exposure: Europe/Nordic Region (EUR)|
|IPOX Europe (IXTE)||-0.31||5.59||19.57|
|IPOX Nordic (IPND)||2.32||5.17||17.32|
|Exposure: Asia-Pacific/China Region (USD)|
|IPOX Asia-Pacific (IPTA)||1.45||2.85||22.36|
|IPOX China C. (IPXUCHCHP)*||2.51||12.29||42.17|
|IPOX China (CNI)||4.19||9.59||36.55|
* Basis for ETPs: FPX US, FPX LN, FPXU FP, FPXI US, TCIP110 IT and CME listed e-mini IPOX 100 U.S. Index Futures [Symbol: IPOZ7].
Global IPO Deal-flow Review and Outlook: Japanese IPOs record strong initial gains / more deals lined up: At least 9 notable (non-China A shares and non-local India) firms commenced trading last week with the average (median) equally-weighted company adding 31.45% (13.50%) based on the difference between final offer and Friday’s close. Japanese vacuum coating machines manufacturer Optorun (6235 JP: 97.19%) and H.K. traded IPO, Chinese orthopedic implants manufacturer AK Medical (1789 HK: 80.00%), recorded as the best performing based on final offer. The two Chinese IPOs in the U.S. last week including pet products producer Dogness International (DOGZ US: 17.00%) and online lender LexinFintech (LX US: 57.78%) also recorded solid performances. While Brazil ‘Burger King’ operator BK Brasil Operação e Assessoria a Restaurantes (BKBR3 BZ: -4.00%) fell below offer. We also note more downsized and postponed deals last week, including Puerto Rico insurance company Advantage Insurance’s $100 million. No significant deals are lined up amid Christmas and holiday season.
|Select IPOs traded (week: 12/18/2017)||Country|
|AK Medical Holdings||China|
|Ayo Technology Solution Ltd||South Africa|
|BK Brasil Operação e Assessoria a Restaurantes||Brazil|
|Dogness International Corp||China|
|LexinFintech Holdings Ltd||China|
|Moriroku Holdings Co Ltd||Japan|
|Optorun Co Ltd||Japan|
|Premium Group Co Ltd||Japan|
|Sumo Group PLC||Britain|
|Select IPOs expected (week: 12/25/2017)||Country|
|Do Day Dream PCL||Thailand|
Josef Schuster is the founder of IPOX Schuster LLC (www.ipoxschuster.com), a Chicago-based Financial Services company specialized in Financial Products Design related to Initial Public Offerings and corporate Spin-offs. He is the chief architect of the IPOX Indexes, a global index group initiated in 2004 that encompasses an index technology allowing for asset-allocation focused exposure to the “going public” effect associated with global IPOs and Spin-offs. Mr. Schuster earned his Bachelor of Arts degree in Business Administration in 1994 from the European Business School, London. Mr. Schuster was also awarded a MSc in Accounting and Finance in August 1996 and a MPhil / PhD in Accounting and Finance in June 2003 from the London School of Economics.
ABOUT THE IPOX INDEXES: Through the range of the IPOX Indexes, market participants have an innovative opportunity to navigate the global IPO and Spin-off market and to track the performance of this economically significant sector more accurately and comprehensively than with any other index group. The IPOX Indexes accomplish the systematic indexation of the aftermarket performance of the IPO and Spin-off sector, while – at the same time – preserving the benefits of diversification. Linked to the IPOX 100 U.S. Index, for example, IPOX-linked investment products available to investors include the pioneering USD million 600, 5-star First Trust U.S. IPO ETF (ticker: FPX). On February 18, 2016, CME Group, the world’s largest exchange operator, launched e-mini IPOX 100 U.S. Index Futures, offering market participants for the first time a tool to manage the aggregate risk associated with U.S. IPOs and Spin-offs.
Disclosure: the author has no position in the stocks mentioned.
Lime Brokerage LLC is not affiliated with these service providers. Data, information, and material (“content”) is provided for informational and educational purposes only. This content neither is, nor should be construed as an offer, solicitation, or recommendation to buy or sell any securities. Any investment decisions made by the user through the use of such content is solely based on the users independent analysis taking into consideration your financial circumstances, investment objectives, and risk tolerance. Lime Brokerage LLC does not endorse, offer or recommend any of the services provided by any of the above service providers and any service used to execute any trading strategies are solely based on the independent analysis of the user.